EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Experience with donanemab over a 1‐year period: observations of side effects and compliance from a regional specialty medical center

Lisa B E Shields iD, Hannah S Hust, Gregory E Cooper, Theresa Kluthe, Rachel N Hart, Andrew P Thaliath, Brandon C Dennis, Stephanie W Freeman, Jessica F Cain, Whoy Y Shang, Kendall M Wasz, Adam T Orr und 3 weitere

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-07 · 18 (3)

DOI: 10.1002/dad2.70438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, online erschienen am 18.08.2026. Verfasst von Lisa B E Shields und 14 weiteren Autor:innen. Beteiligte Einrichtung: Norton Neuroscience Institute Norton Healthcare Louisville Kentucky USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION The anti‐amyloid monoclonal antibody donanemab (Kisunla™) treats patients with mild cognitive impairment or mild Alzheimer's disease. METHODS This study highlights 51 patients who received at least one donanemab infusion at our memory center between October 4, 2024 and October 3, 2025. RESULTS Of the 48 patients who underwent at least one surveillance brain MRI after starting donanemab, 10 (20.8%) had ARIA detected. ε4 carriers more frequently displayed amyloid‐related imaging abnormalities (ARIA‐cortical superficial hemosiderosis/microhemorrhages [ARIA‐H] and/or ARIA‐edema/effusion) ( p = 0.033) and ARIA‐H ( p = 0.020) compared to ε4 non‐carriers. No patients developed symptomatic ARIA. Seven (13.7%) patients experienced infusion‐related side effects. Eight (15.7%) patients discontinued donanemab due to ARIA progression (5), severe infusion reactions (2), and need for anticoagulants (1). DISCUSSION Donanemab may be safely used in a real‐world setting with structured monitoring. ARIA was observed in 20.8% of patients in this implementation cohort. Larger‐scale multicenter data are needed to benchmark rates.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseadverse effectsamyloid‐related imaging abnormalitiesanti‐amyloid therapydonanemabmild cognitive impairmentmild dementia

Autor:innen und Institutionen

  • Norton Neuroscience Institute Norton Healthcare Louisville Kentucky USA.
  • Norton Research Institute Norton Healthcare Louisville Kentucky USA.
  • Department of Pediatrics University of Louisville School of Medicine Louisville Kentucky USA.
  • Department of Neurological Surgery University of Louisville School of Medicine Louisville Kentucky USA.
  • Department of Medicine University of Louisville School of Medicine Louisville Kentucky USA.

ORCID-Profile: Lisa B E Shields, Kenneth G Pugh

Zitieren

APA

Shields, L. B. E., Hust, H. S., Cooper, G. E., Kluthe, T., Hart, R. N., Thaliath, A. P., Dennis, B. C., Freeman, S. W., Cain, J. F., Shang, W. Y., Wasz, K. M., Orr, A. T., Shields, C. B., Barve, S. S., & Pugh, K. G. (2026). Experience with donanemab over a 1‐year period: observations of side effects and compliance from a regional specialty medical center. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(3). https://doi.org/10.1002/dad2.70438

Vancouver

Shields LBE, Hust HS, Cooper GE, Kluthe T, Hart RN, Thaliath AP, et al. Experience with donanemab over a 1‐year period: observations of side effects and compliance from a regional specialty medical center. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(3). doi:10.1002/dad2.70438

BibTeX
@article{Shields2026,
  author = {Shields, Lisa B E and Hust, Hannah S and Cooper, Gregory E and Kluthe, Theresa and Hart, Rachel N and Thaliath, Andrew P and Dennis, Brandon C and Freeman, Stephanie W and Cain, Jessica F and Shang, Whoy Y and Wasz, Kendall M and Orr, Adam T and Shields, Christopher B and Barve, Shirish S and Pugh, Kenneth G},
  title = {Experience with donanemab over a 1‐year period: observations of side effects and compliance from a regional specialty medical center},
  journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
  year = {2026},
  volume = {18},
  number = {3},
  doi = {10.1002/dad2.70438}
}
Kostenlos starten →